Jon Mcclelland Lockard

Array ( [id] => 20246866 [patent_doc_number] => 20250295735 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-09-25 [patent_title] => ACTIVIN RECEPTOR TYPE IIA VARIANTS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 19/229468 [patent_app_country] => US [patent_app_date] => 2025-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18278 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19229468 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20308065 [patent_doc_number] => 20250325694 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-10-23 [patent_title] => ANTIBODY-OLIGONUCLEOTIDE CONJUGATE COMPOSITIONS AND METHODS OF INDUCING DMD EXON 52 SKIPPING [patent_app_type] => utility [patent_app_number] => 19/097593 [patent_app_country] => US [patent_app_date] => 2025-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32436 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19097593 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19754407 [patent_doc_number] => 20250042972 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-06 [patent_title] => VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION [patent_app_type] => utility [patent_app_number] => 18/924707 [patent_app_country] => US [patent_app_date] => 2024-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4797 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18924707 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19554933 [patent_doc_number] => 20240366725 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE [patent_app_type] => utility [patent_app_number] => 18/784736 [patent_app_country] => US [patent_app_date] => 2024-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8285 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -54 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18784736 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19528204 [patent_doc_number] => 20240352106 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-24 [patent_title] => PHARMACEUTICAL COMPOSITIONS TARGETING IMMUNE-MEDIATED PROCESSES IN NEURODEGENERATIVE DISEASE [patent_app_type] => utility [patent_app_number] => 18/650019 [patent_app_country] => US [patent_app_date] => 2024-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25232 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18650019 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19300046 [patent_doc_number] => 20240228615 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-11 [patent_title] => ANTI-TREM-1 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/621534 [patent_app_country] => US [patent_app_date] => 2024-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32931 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -54 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18621534 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19815099 [patent_doc_number] => 20250073306 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-06 [patent_title] => FORMULA OF NEUREGULIN PREPARATION [patent_app_type] => utility [patent_app_number] => 18/618991 [patent_app_country] => US [patent_app_date] => 2024-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12028 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18618991 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19343626 [patent_doc_number] => 20240252589 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-01 [patent_title] => AGENT FOR ENHANCING PHAGOCYTOSIS ABILITY OF NEUTROPHILS [patent_app_type] => utility [patent_app_number] => 18/595513 [patent_app_country] => US [patent_app_date] => 2024-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5965 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18595513 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19975920 [patent_doc_number] => 12343376 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-01 [patent_title] => Methods for inhibiting diazepam binding protein [patent_app_type] => utility [patent_app_number] => 18/444102 [patent_app_country] => US [patent_app_date] => 2024-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 27 [patent_no_of_words] => 17101 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18444102 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19111233 [patent_doc_number] => 20240122983 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => FLT3L-BASED CHIMERIC PROTEINS [patent_app_type] => utility [patent_app_number] => 18/396206 [patent_app_country] => US [patent_app_date] => 2023-12-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29085 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -47 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18396206 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19246842 [patent_doc_number] => 20240197826 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-20 [patent_title] => USE OF THE EXTRACELLULAR DOMAIN OF TRANSFERRIN RECEPTOR 2 FOR THE DIAGNOSIS AND TREATMENT OF PRIMARY OR SECONDARY SCLEROSING DISEASES [patent_app_type] => utility [patent_app_number] => 18/534366 [patent_app_country] => US [patent_app_date] => 2023-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4591 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18534366 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19034228 [patent_doc_number] => 20240084043 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => METHODS OF TREATING AN EYE DISORDER [patent_app_type] => utility [patent_app_number] => 18/504723 [patent_app_country] => US [patent_app_date] => 2023-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64633 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -63 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18504723 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19302088 [patent_doc_number] => 20240230665 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2024-07-11 [patent_title] => GENERATION OF HUMAN ALLERGEN- AND HELMINTH-SPECIFIC IGE MONOCLONAL ANTIBODIES FOR DIAGNOSTIC AND THERAPEUTIC USE [patent_app_type] => utility [patent_app_number] => 18/497432 [patent_app_country] => US [patent_app_date] => 2023-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29744 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18497432 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19302088 [patent_doc_number] => 20240230665 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2024-07-11 [patent_title] => GENERATION OF HUMAN ALLERGEN- AND HELMINTH-SPECIFIC IGE MONOCLONAL ANTIBODIES FOR DIAGNOSTIC AND THERAPEUTIC USE [patent_app_type] => utility [patent_app_number] => 18/497432 [patent_app_country] => US [patent_app_date] => 2023-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29744 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18497432 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19111280 [patent_doc_number] => 20240123030 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders [patent_app_type] => utility [patent_app_number] => 18/496472 [patent_app_country] => US [patent_app_date] => 2023-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9075 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18496472 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19157772 [patent_doc_number] => 20240150479 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-09 [patent_title] => Liquid Pharmaceutical Composition Comprising an Anti-IL-6 Receptor Antibody [patent_app_type] => utility [patent_app_number] => 18/494630 [patent_app_country] => US [patent_app_date] => 2023-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9212 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18494630 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19318371 [patent_doc_number] => 20240239914 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-18 [patent_title] => HUMAN CD163 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/491682 [patent_app_country] => US [patent_app_date] => 2023-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63432 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18491682 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19510570 [patent_doc_number] => 20240342256 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-17 [patent_title] => INJECTION PARADIGM FOR ADMINISTRATION OF BOTULINUM TOXINS [patent_app_type] => utility [patent_app_number] => 18/376196 [patent_app_country] => US [patent_app_date] => 2023-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18807 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18376196 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18986449 [patent_doc_number] => 20240058418 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-22 [patent_title] => High Concentration VEGF Receptor Fusion Protein Containing Formulations [patent_app_type] => utility [patent_app_number] => 18/367444 [patent_app_country] => US [patent_app_date] => 2023-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24765 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18367444 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19034136 [patent_doc_number] => 20240083951 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => TARGETING ALPHA2DELTA-1-BOUND GLUTAMATE RECEPTORS FOR TREATING DISEASES AND DISORDERS [patent_app_type] => utility [patent_app_number] => 18/465145 [patent_app_country] => US [patent_app_date] => 2023-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53836 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18465145 [rel_patent_id] =>[rel_patent_doc_number] =>)